| Wei Livy Fan, MD | |
|
8900 Van Wyck Expy, Jamaica Hospital Medical Center, Dept Emergency Med, Jamaica, NY 11418-2832 | |
| (718) 206-6070 | |
| Not Available |
| Full Name | Wei Livy Fan |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 19 Years |
| Location | 8900 Van Wyck Expy, Jamaica, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134354483 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 253053 (New York) | Secondary |
| 207P00000X | Emergency Medicine | C153972 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Garfield Medical Center | Monterey park, CA | Hospital |
| St Mary Medical Center | Apple valley, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gem Medical Group Corporation | 3072984400 | 51 |
| Cep America - California | 6103739131 | 954 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667843 PECOS PAC ID: 6103739131 Enrollment ID: O20040121000458 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Entity Name | Michael S. Agron, M.d., Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699716100 PECOS PAC ID: 2668360736 Enrollment ID: O20040707000788 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Entity Name | Usc Care Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902846306 PECOS PAC ID: 0446157747 Enrollment ID: O20050512000412 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Entity Name | Golden West Emergency Medical Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053680298 PECOS PAC ID: 8628098936 Enrollment ID: O20051201000582 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Entity Name | Apex Emergency Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265711089 PECOS PAC ID: 4688844277 Enrollment ID: O20110909002790 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Entity Name | Apex Emergency Medical Group- Chapman Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659912798 PECOS PAC ID: 0840626354 Enrollment ID: O20200131001456 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Entity Name | Spectrum Emergency Physicians Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831783729 PECOS PAC ID: 6103233705 Enrollment ID: O20210326001500 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Entity Name | Seven Star Hospital Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043813140 PECOS PAC ID: 4789083338 Enrollment ID: O20210601002852 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Entity Name | Gem Medical Group Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689364721 PECOS PAC ID: 3072984400 Enrollment ID: O20230124000274 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Entity Name | Anaheim Emergency Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114626017 PECOS PAC ID: 9133585029 Enrollment ID: O20230518003235 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wei Livy Fan, MD 8900 Van Wyck Expy, Jamaica Hospital Medical Center, Dept Emergency Med, Jamaica, NY 11418-2832 Ph: () - | Wei Livy Fan, MD 8900 Van Wyck Expy, Jamaica Hospital Medical Center, Dept Emergency Med, Jamaica, NY 11418-2832 Ph: (718) 206-6070 |
News Archive
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
› Verified 3 days ago
Dr. Chetankumar Patel, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 8900 Van Wyck Expy, Jamaica, NY 11418 Phone: 718-206-6000 | |
Dr. Elbert Ching, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 8268 164th St, Jamaica, NY 11432 Phone: 917-584-0819 | |
Dr. Maria Teresa Lechuga, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 8900 Van Wyck Expy, Jamaica, NY 11418 Phone: 718-206-6000 | |
Dr. Sergey Galustyan, M.D. Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 8900 Van Wyck Expy, Jamaica, NY 11418 Phone: 718-206-6000 | |
Dr. Revanord Pierre-louis, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 15211 89th Ave, Jamaica, NY 11432 Phone: 212-563-2497 Fax: 212-563-0605 | |
Alfredo Wong, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 15211 89th Ave, Rm.#5100, Jamaica, NY 11432 Phone: 212-533-1701 | |
Dr. Santhosh Alex, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 8900 Van Wyck Expressway, Jamaica, NY 11418 Phone: 718-206-6600 Fax: 631-454-4161 |